Merck’s Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer – Fortune
Fortune |
Merck's Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer
Fortune New study results released Monday continue to cement drug giant Merck's status as the force to be reckoned with in the lung cancer treatment space. Merck's flagship cancer immunotherapy Keytruda (or pembrolizumab), combined with chemotherapy, helped … Merck BMS Roche lung cancer immunotherapy data – Business Insider Merck lung cancer trial boosts immunotherapy hopes – Financial Times Merck, Bristol-Myers immunotherapies impress in key lung cancer … |
